beta

AIM

AIM ImmunoTech, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.

Market Cap: 3.76 Million

Primary Exchange: NYSE American

Website: http://www.hemispherx.net

Shares Outstanding: 8.26 Million

Float: 7.92 Million

Dividend: (%)

Beta: 0.528681704887609

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 142 trading days

From: 2019-06-12 To: 2019-12-13

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud